首页> 美国卫生研究院文献>Neuro-Oncology >PATH-03. DIFFERENCES IN CLINICAL COURSE OF GROUP-A AND GROUP-B POSTERIOR FOSSA EPENDYMOMA (PFA PFB) AS DEFINED BY H3K27ME3 IMMUNOHISTOCHEMICAL ANALYSIS
【2h】

PATH-03. DIFFERENCES IN CLINICAL COURSE OF GROUP-A AND GROUP-B POSTERIOR FOSSA EPENDYMOMA (PFA PFB) AS DEFINED BY H3K27ME3 IMMUNOHISTOCHEMICAL ANALYSIS

机译:路径-03。 H3K27ME3免疫组织化学分析(PFAPFB)临床过程中临床进程的差异如H3K27ME3免疫组化分析

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Posterior fossa ependymoma is classified as PFA and PFB based on underlying genetic/mutational characteristics, and PFA is reported to have poor prognosis compared to PFB. Recently, immunohistochemical findings of negative H3K27me3 have been reported to suggest PFA and attracted the attention as a surrogate marker. We classified our cases into PFA and PFB guided by immunohistochemical staining results of H3K27me3 and examined their clinical course.
机译:基于潜在的遗传/突变特征,据报道,基于潜在的遗传/突变特征,PFA的PFA和PFB分为PFA和PFB,与PFB相比预后差。最近,据报道,负H3K27ME3的免疫组织化学发现表明PFA并吸引了作为替代标记的注意力。我们将案例分类为PFA和PFB,由H3K27ME3的免疫组化染色结果引导,并检查了他们的临床过程。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号